Sergey Terushkin, MD, FACS Dr
Individuals with the following conditions may be at heightened risk and should be assessed carefully: Pre-existing arrhythmias , including atrial fibrillation or supraventricular tachycardia, given the drug's association with elevated resting heart rate Heart failure , particularly where heart rate control is a key management goal Ischaemic heart disease , where any increase in myocardial oxygen demand could be clinically significant Uncontrolled hypertension , although retatrutide may itself reduce blood pressure over time Patients on rate-modifying medications such as beta-blockers or calcium channel blockers whilst no direct pharmacokinetic drugdrug interactions have been established, the heart rate effects of retatrutide may complicate clinical management and require closer monitoring Patients with a recent acute coronary syndrome, decompensated heart failure, or unstable angina are typically excluded from clinical trials of this class of agent
Prasad CV et al
Patients often report an improved quality of life due to weight loss, better blood sugar control, and reduced hunger
The product exceeds 60 days from the purchase date
This dual-direction approach explains why retatrutide results showed greater weight loss in a shorter period without participants reaching a metabolic plateau where the body adapts and weight loss stalls